Tumor sample context
Tumor type, collection site, sample condition, expected timing and available ethics documentation.
Pancreatic cancer PDO
Use conventional PDOs for pancreatic epithelial and drug-response studies, with ALI or custom co-culture added when stromal or immune context is important.
CK19CD3CD8CD107a
Model source
Patient pancreatic cancer tissue
Culture / format
PDO · ALI/custom co-culture
Available study data
TRiCBIO pancreatic cancer PDO culture and study data
Model characterization
Epithelial and T-cell readouts in pancreatic PDOs
Source-tissue/PDO histology and CK19 and CD3 images show pancreatic epithelial and T-cell context. Separate flow panels show CD3, CD8 and CD107a across treatment conditions.
View imagePDAC tissue and PDO comparison: H&E and bright-field images show tissue morphology; CK19 labels epithelial cells and CD3 labels sample-associated T cells.
TRiCBIO PDAC PDO 2.0 study data
View imageT-cell analysis in PDAC PDOs: flow cytometry compares CD3 and CD8 cell populations and the degranulation marker CD107a across treatment conditions.
Study dataStudy planning
Models and assays for your study
Tumor type, sample condition, candidate and intended comparison guide the culture format, controls and assays.
Candidate and study objective
Modality, dosing plan, controls and the response or comparison the study should address.
Assays and deliverables
Planned histology, flow, molecular or functional assays, together with preferred data and report formats.
Study design
PDAC biology and candidate response
PDAC is dense and sample-variable. Confirm tumor epithelial identity and culture quality, then configure penetration, bystander or immune endpoints around the candidate mechanism.
Confirm source and epithelial identity
Review primary or metastatic site, pathology and sample state, then confirm the model with morphology and epithelial markers such as CK19.
Select the required complexity
Use conventional PDO for tumor-cell efficacy comparisons and add ALI or custom co-culture for tissue penetration, bystander-killing or immune-interaction readouts.
Set mechanism-linked endpoints
Select viability, apoptosis, histology, penetration imaging and immune readouts according to the small-molecule, ADC, antibody or immune mechanism.
Interpret response in tissue context
Integrate model identity, drug distribution, killing and microenvironment signals to compare candidates and define the next study.
Research applications
Recommended applications
- Small molecules and combinations
- Epithelial–stromal research
- Immunotherapy studies
Assays & QC
Tumor identity, efficacy and immune readouts
Key markers
CK19CD3CD8CD107a
Available assays
- H&E
- Alcian Blue
- IF / IHC
- Flow cytometry
QC approach
Characterization combines epithelial markers such as CK19 and histology with immune or functional endpoints selected for the study.
Study & delivery
Model characterization, treatment data and reporting
Choose a supplied model or a TRiCBIO-run study. Typical deliverables include histology, functional data and a study report.
Study design
Marker, stromal-context and immune readout panels are selected from the sample baseline and study objective.
Related solutions
Related study options
PROJECT DISCUSSION
Discuss a pancreatic cancer PDO study
Tell us about the tumor type, samples, candidate and results you want to compare. Our scientists will help plan your pancreatic cancer PDO study.